Savaysa (edoxaban) / Daiichi Sankyo - LARVOL DELTA

Bleeding Risk in Patients Receiving Acalabrutinib or Zanubrutinib with Direct Oral Anticoagulants: A Retrospective Cohort Study (HOPA 2026) - "Although bleeding risk with ibrutinib plus direct oral anticoagulants (DOACs) is well described, data evaluating bleeding outcomes with second-generation BTKis, including acalabrutinib and zanubrutinib, used concurrently with DOACs remain limited... This retrospective cohort study will include adult patients with CLL, MCL, or WM treated with acalabrutinib or zanubrutinib in combination with a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) between May 1, 2022, and May 1, 2024, at Atrium Health Levine Cancer Institute... Results pending."

Retrospective data • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Hemophilia • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Thrombocytopenia • Waldenstrom Macroglobulinemia

From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review. (PubMed, Cancers (Basel)) - "For long-term management, LMWH may be replaced by direct oral anticoagulants such as apixaban, edoxaban, or rivaroxaban. LWMH and unfractionated heparin (UFH) are preferred options for VTE prophylaxis. Novel therapies, including factor XI inhibitors, show efficacy comparable to LMWH while offering a better safety profile."

Journal • Review • Cardiovascular • Oncology • Pancreatic Cancer • Solid Tumor • Venous Thromboembolism • PDPN

ATHEROEMBOLIC RENAL DISEASE IN A PATIENT WITH SYSTEMIC EMBOLIC MANIFESTATIONS: A DIAGNOSTIC AND MANAGEMENT CHALLENGE (ISN-WCN 2026) - "Systemic embolic predisposing factors and manifestations in this patient comprised:• Ophthalmic: retinal microembolus (May 2024)• Neurological: hemispheric ischaemic stroke (July 2024), chronic MRI evidence of cerebral ischaemia• Renal: biopsy proven AERD• Cardiac: paroxysmal AF, left ventricular systolic dysfunction• Vascular: bilateral carotid stenoses (left 70–89 %, right 50–59 %)Despite initiation of anticoagulation (edoxaban), antihypertensive therapy and lipid lowering medication, the patient's estimated glomerular filtration rate (eGFR) declined to 14 mL/min/1.73 m2 by early 2025, prompting preparation for dialysis.Download: Download high-res image (214KB)Download: Download full-size imageFigure 1...Management is primarily supportive, centred on withdrawal of precipitating agents (e.g., NSAIDs, dual antiplatelets), aggressive cardiovascular risk reduction, and early planning for renal replacement therapy. Clinicians should maintain a high index of suspicion..."

Clinical • Acute Kidney Injury • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Ischemic stroke • Metabolic Disorders • Multiple Myeloma • Nephrology • Ophthalmology • Peripheral Arterial Disease • Renal Disease • Type 2 Diabetes Mellitus

BEYOND CHADS2-VASC: QUESTIONING SYSTEMIC ANTICOAGULATION IN ADVANCED CHRONIC RENAL DISEASE WITH AURICULAR FIBRILATION (ISN-WCN 2026) - "Even the most recent clinical guidelines recommend individualized use of these scales in this subgroup of patients.Regarding treatment, vitamin K antagonist anticoagulants, such as warfarin or acenocoumarol, have historically been the most widely used drugs...In addition, INR control is especially complex in these patients, with increased risk of overanticoagulation.Direct-acting oral anticoagulants, such as apixaban, edoxaban, rivaroxaban and dabigatran, have demonstrated a better safety profile in certain contexts, with lower bleeding risk than vitamin K antagonist anticoagulants...This scale allows a stratification more adjusted to the renal profile and contributes to reduce unnecessary exposure to anticoagulant treatments with significant bleeding risk.It is necessary to promote a multidisciplinary and individualized approach in the assessment of thromboembolic and bleeding risk in this population, integrating the nephrologist in the therapeutic decision-making..."

Metastases • Atrial Fibrillation • Calciphylaxis • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Peripheral Arterial Disease • Pulmonary Arterial Hypertension • Rare Diseases • Renal Disease

Non-cirrhotic portal-splenic-mesenteric vein thrombosis unmasking JAK2 V617F-positive polycythemia vera. (PubMed, Clin J Gastroenterol) - "Edoxaban 30 mg once daily (body weight < 60 kg) was initiated without interruption or bleeding, and therapeutic phlebotomy was initiated to control the hematocrit. Follow-up computed tomography on day 78 demonstrated marked thrombus reduction with partial re-opacification of the main portal vein, and the patient continued to have a stable clinical course. This case highlights triple-site, non-cirrhotic SVT as a potential presenting feature of PV and supports early JAK2 V617F and erythropoietin testing, coupled with parallel anticoagulation and PV-directed management, in unexplained non-cirrhotic SVT."

JAK2V617F • Journal • Cardiovascular • Fibrosis • Hematological Disorders • Immunology • Myeloproliferative Neoplasm • Oncology • Pain • Polycythemia Vera • Thrombosis • JAK2

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation (clinicaltrials.gov) - P4 | N=150 | Completed | Sponsor: China National Center for Cardiovascular Diseases | Recruiting ➔ Completed

Trial completion • Atrial Fibrillation • Cardiovascular

Advancing Point-of-Care Analysis: The Future of Thromboelastographic DOAC-Detection: A Systematic Review. (PubMed, Semin Thromb Hemost) - "For direct factor Xa inhibitors-rivaroxaban, apixaban, and edoxaban-modified assays using Russell's Viper Venom, factor Xa-based reagents, and low-tissue-factor activation showed variable but generally good correlations with drug levels (r = 0.571-0.969). Ecarin-based tests appear reliable for dabigatran, while Russell's Viper Venom and low-tissue-factor approaches may enable detection of direct factor Xa inhibitors. However, further clinical validation and standardization are required before routine implementation."

Journal • Cardiovascular • Ischemic stroke

Safety of prothrombin complex concentrate for emergency surgery according to the oral factor Xa inhibitor level. (PubMed, Thromb Haemost) - "Results PCC at a median dose of 2000 units (interquartile range, 2000-2000) was administered to 227 patients on apixaban (143; 63%), rivaroxaban (72; 32%), or edoxaban (12;5%). Conclusion The risk of thromboembolism after 4F-PCC in patients on XaI and emergency surgery/invasive procedures appears to be similar among patients with preoperative XaI levels that are high, low or not measured. This information might be helpful in settings where rapid anti Xa testing is unavailable."

Journal • Cardiovascular • Venous Thromboembolism

Efficacy and Safety of DOACs in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: The Liverpool AF-Falls Project. A Systematic Review and Bayesian Network Meta-analysis. (PubMed, Drugs Aging) - "DOACs appear to have different efficacy and safety profiles and overall are preferable over VKAs in patients with AF with a history or risk of falls. Because of bias, further research is warranted."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular

Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial. (PubMed, J Am Heart Assoc) - P4 | "In patients with AF and stable coronary artery disease, edoxaban monotherapy significantly reduced net adverse clinical events at 12 months compared with dual antithrombotic therapy, irrespective of AF pattern."

Clinical • Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

A Novel Approach to Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Other Medications Including Non-Steroidal Anti-Inflammatory Drugs and Antidepressants (THSNA 2026) - " Risk of GIB for OAC products obtained from pivotal studies were: 1.99% for apixaban; 3.15% for rivaroxaban; 2.99% for dabigatran; 3.31% for edoxaban; and 2.00% for warfarin. The odds of GIB for NSAIDs ranged from 1.16 (95% CI:0.84-1.61) for celecoxib to 20.67 (95% CI:14.56-29.34) for ketorolac. Odd ratios for GIB among SSRI/SNRI ranged from 1.31 (95% CI:1.07-1.62) for paroxetine to 1.50 (95% CI:1.32-1.70) for venlafaxine. Risk of GIB for other factors included: persons over 65 years of age (OR=2.50, 95% CI:1.2–5.5); previous history of GIB (OR=5.13, 95% CI:3.95–6.67); aspirin use (OR=1.31, 95% CI:0.93-1.85); antiplatelets use (OR=1.95, 95% CI:1.68-2.27); and corticosteroids use (OR=1.68, 95% CI:1.49-1.90)... The DIOAC-GIB incorporates drug interactions with OACs and had good correlation with other bleeding risk scores. DIOAC-GIB may help identify high-risk patients that benefit from tailored prescribing. No part of this publication may be reproduced, distributed, or..."

Clinical • Gastroenterology

Rethinking Extended Anticoagulation in Cancer: Is Less More? A Systematic Review and Meta-Analysis of Clinical Trials (THSNA 2026) - " A systematic search of PubMed, Embase, and Scopus through June 2025 identified RCTs evaluating reduced-dose versus standard-dose regimens of apixaban rivaroxaban or edoxaban in adults with active cancer and prior VTE who had completed ≥6 months of anticoagulation. In cancer patients requiring extended anticoagulation beyond six months, reduced-dose DOACs provide comparable protection against recurrent VTE without increasing mortality and are associated with significantly lower CRNMB and composite bleeding compared with standard-dose therapy. Although major bleeding was numerically lower with reduced dosing, significance was not reached. These findings support reduced-dose DOACs as a safe and effective long-term strategy for secondary prevention of CAT."

Retrospective data • Review • Oncology • Respiratory Diseases • Venous Thromboembolism

BEYOND WARFARIN: ARE DIRECT ORAL ANTICOAGULANTS THE FUTURE OF LVAD ANTICOAGULATION? A MULTI-CENTER PROPENSITY-MATCHED ANALYSIS (ACC 2026) - " Using the TriNetX U.S. Collaborative Network (71 healthcare organizations), we identified adult LVAD recipients treated with DOACs (apixaban, rivaroxaban, dabigatran, or edoxaban) or warfarin. In this large real-world cohort, DOACs were linked to reduced mortality, lower thrombotic and bleeding complications compared to warfarin. Differences in follow-up duration may reflect evolving practice patterns and warrant cautious interpretation. These findings warrant urgent prospective trials to evaluate DOAC safety and redefine anticoagulation standards in LVAD care."

Clinical • Cardiovascular • Hematological Disorders • Infectious Disease • Ischemic stroke • Thrombosis

IS ASPIRIN ENOUGH? OUTCOMES OF ASPIRIN MONOTHERAPY COMPARED WITH ASPIRIN PLUS DOAC AFTER LAAO (ACC 2026) - "DOACs included Apixaban, Rivaroxaban, Dabigatran, Edoxaban. In AF patients undergoing LAAO, aspirin alone demonstrated comparable outcomes to aspirin combined with a DOAC for mortality, ischemic stroke, and major bleeding at 1 year. These findings suggest aspirin monotherapy may be an acceptable strategy following LAAO."

Monotherapy • Atrial Fibrillation • Cardiovascular • CNS Disorders • Ischemic stroke

EVALUATION OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY LOW BODY WEIGHT (ACC 2026) - " Adult patients with a history of atrial fibrillation and a BMI ≤ 18.5 kg/m² who were prescribed a DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) between August 2020 and August 2024 will be included in the study and retrospectively identified from Brigham and Women's Hospital inpatient and outpatient records. Results of this study will add valuable data to the literature and inform directions for future studies."

Clinical • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Myocardial Infarction

SEX-SPECIFIC OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN POST-MYOCARDIAL INFARCTION THROMBUS (ACC 2026) - " Using the TriNetX Global Collaborative Network, we identified adults (≥18 years) with post-MI LV or atrial thrombosis treated with a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) within 7 days of diagnosis. We excluded patients with mechanical valves, rheumatic mitral stenosis, or prior warfarin use... In patients with post-MI LV or atrial thrombi treated with DOACs, men and women had comparable one-year risks of stroke, mortality, and major bleeding. Women experienced higher rates of recurrent thromboembolism, while men trended toward more ischemic strokes. These findings underscore the need for sex-specific considerations in anticoagulation strategies after MI."

Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Thrombosis

AFEBRILE PROSTHETIC VALVE ENDOCARDITIS OBSCURED BY HEMOLYSIS: A POST-HEMI-COMMANDO PUZZLE (ACC 2026) - "Heparin-induced thrombocytopenia (HIT) prompted change from heparin to argatroban, then edoxaban; recurrent atrial fibrillation was cardioverted...He received 6 weeks ceftriaxone via peripherally inserted central catheter and intravenous immunoglobulin; corticosteroids were started after infection control with rapid recovery... Afebrile, hemolysis-predominant PVE after complex valve surgery warrants early TEE, culture-directed antibiotics, and staging immunosuppression until infection control to achieve recovery without reoperation or disability."

Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Fibrosis • Hematological Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Thrombocytopenia • CRP

OUTCOMES OF DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN IN HIV PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY-MATCHED ANALYSIS (ACC 2026) - "We identified adult patients with HIV and AF treated with either DOACs (apixaban, rivaroxaban, edoxaban, or dabigatran) or warfarin. Among HIV patients with atrial fibrillation, DOACs were associated with lower risks of stroke, intracranial hemorrhage, GI bleeding, and all-cause mortality compared to warfarin. Our findings support the safety and efficacy of DOACs over warfarin in this underrepresented population and highlight the need for inclusive anticoagulation guidelines. Prospective studies are needed to confirm these findings and optimize care in this high-risk group."

Clinical • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Renal Disease

Safety and Tolerability of Edoxaban in Filipino Patients With Non-valvular Atrial Fibrillation: A Pilot Post-marketing Surveillance Study. (PubMed, Cureus) - "In this real-world Filipino cohort, edoxaban demonstrated a favorable safety profile with zero major bleeding events over six months of therapy. Despite a high-risk profile and significant comorbidities, these findings align with global phase III and post-marketing data, supporting edoxaban as a safe anticoagulation option for Filipino patients with NVAF."

Journal • P4 data • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction

Clinical Effectiveness and Bleeding Outcomes of Edoxaban for Cancer-Associated Venous Thromboembolism in Korean Patients: A Prospective, Multicenter, Single-Arm, Observational Cohort Study (ICKSH 2026) - No abstract available

Clinical • Observational data • Oncology • Venous Thromboembolism

SIFT: Thrombolysis in Factor Xa-inhibitors Trial (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Guri Hagberg | N=300 ➔ 400

Enrollment change • Cardiovascular • Ischemic stroke

Rivaroxaban in comparison with low molecular weight heparin for the treatment of cancer-associated thrombosis: a systematic review and meta-analysis (PubMed, Angiol Sosud Khir) - "In patients with cancer-associated thrombosis, the use of rivaroxaban in comparison with LMWH is associated with a reduced risk of VTE recurrence without an increase in the risk of major bleeding and does not affect all-cause mortality."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Oncology • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (clinicaltrials.gov) - P3 | N=1204 | Not yet recruiting | Sponsor: Sunnybrook Health Sciences Centre

New P3 trial • Alzheimer's Disease • Cardiovascular • Ischemic stroke

COMPARATIVE EFFECTIVENESS OF INDIVIDUAL NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A BINATIONAL POPULATION-BASED COHORT STUDY (ISPOR 2026) - "In real-world practice, initiation of NOAC therapy was associated with a lower risk of stroke compared with warfarin in patients with AF and MASLD, with edoxaban showing the lowest stroke risk in terms of point estimates. These findings were consistently observed at the national level across two independent East Asian population-based cohorts."

Clinical • HEOR • Atrial Fibrillation • Cardiovascular • Hepatology • Ischemic stroke • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

DIRECT ORAL ANTICOAGULANTS IN BRAZIL: PRICE TRENDS, MARKET COMPETITION, AND POLICY IMPLICATIONS (ISPOR 2026) - "Information on patent expiration was obtained from the Brazilian National Institute of Industrial Property (INPI). There are currently 27 laboratories registered for rivaroxaban (18 active), 16 for apixaban (7 active), 2 for dabigatran (1 active), 1 for edoxaban (1 active), and 3 for warfarin (2 active). The coverage of DOACs within SUS was largely rejected due to high prices at the time of health technology assessments. However, increased market competition led to substantial price reductions, highlighting the need for reassessment of these technologies."

Atrial Fibrillation • Cardiovascular